C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 27 PLN -0.18%
Market Cap: 1.5B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Celon Pharma SA
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Celon Pharma SA
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
Celon Pharma SA
WSE:CLN
Total Equity
zł459.4m
CAGR 3-Years
8%
CAGR 5-Years
1%
CAGR 10-Years
N/A
M
Molecure SA
WSE:MOC
Total Equity
zł100.9m
CAGR 3-Years
-11%
CAGR 5-Years
4%
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
Total Equity
zł1.4m
CAGR 3-Years
30%
CAGR 5-Years
18%
CAGR 10-Years
N/A
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.4B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
9.2 PLN
Overvaluation 66%
Intrinsic Value
Price
C

See Also

What is Celon Pharma SA's Total Equity?
Total Equity
459.4m PLN

Based on the financial report for Jun 30, 2024, Celon Pharma SA's Total Equity amounts to 459.4m PLN.

What is Celon Pharma SA's Total Equity growth rate?
Total Equity CAGR 5Y
1%

Over the last year, the Total Equity growth was -2%. The average annual Total Equity growth rates for Celon Pharma SA have been 8% over the past three years , 1% over the past five years .

Back to Top